Abstract 1698
Background
Although gemcitabine plus nab–paclitaxel (GnP) is a standard treatment for advanced pancreatic cancer as the result of phase III trial ((MPACT), its therapeutic benefit for elderly patients is unclear. This study aimed to assess the effectiveness and safety of GnP for these patients.
Methods
We retrospectively enrolled patients aged > =75 years in whom GnP was initiated as first–line treatment for advanced pancreatic cancer between December 2014 and December 2016. Overall survival and progression–free survival according to disease status were calculated using Kaplan–Meier method. Objective response was estimated according to RECISTv1.1. Adverse events were evaluated according to based on the Common Terminology Criteria of Adverse Events version4.0. The incidence of adverse events and early discontinuation (i.e., treatment discontinuation due to adverse events within 2 months from initiation) was compared via Fishers’ exact test for univariate analysis and via logistic regression model with step wise method for multivariate analysis.
Results
The cohort comprised 116 selected patients with a median age of 77 years (range: 75–84 years). Within a median follow-up of 13 months, the median overall survival and progression-free survival of locally advanced cancer patients were 21.8 and 12.1 months, respectively. In patients with metastasis, these were 13.3 and 5.9 months. The response rate was 31% and the disease control rate was 81%. Within the first 2 months of treatment, grade 4 hematological and grade 3–4 non-hematological toxicities were observed in 10 and 23 patients, respectively. Early treatment discontinuation of GnP occurred in 12 patients, and the associated risk factors were age > =80 years [odds ratio (OR), 9.43; 95% confidence interval (CI), 2.25–39.60] and serum albumin <35 g/L (OR, 5.12; 95% CI, 1.11–23.61).
Conclusions
GnP in selected patients aged > =75 years showed acceptable toxicities and comparable effectiveness to that in the previous studies of the non-elderly population, but patients aged > =80 years and with serum albumin <35 d/L should be carefully assessed for treatment eligibility.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Satoshi Kobayashi.
Funding
Has not received any funding.
Disclosure
M. Ozaka: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): Novartis Pharma; Honoraria (self): Bayer Yakuhin; Honoraria (self): Yakult Honsha; Honoraria (self): Eisai; Honoraria (self): EA Pharma. S. Kobayashi: Honoraria (self), Research grant / Funding (institution): Taiho pharmaceutical; Honoraria (self): Boston Scientific; Honoraria (self), Speaker Bureau / Expert testimony: Kyowa Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Speaker Bureau / Expert testimony: Bayer Yakuhin; Honoraria (self): Teijin Pharma; Honoraria (self), Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Takara Bio; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): MSD Oncology; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Takeda. M. Ikeda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer Yakuhin; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): Yakult; Honoraria (self): Otsuka Pharmaceutical; Honoraria (self): Nobel Pharma; Honoraria (self), Advisory / Consultancy: Daiichi-Sankyo; Honoraria (self): Sumitomo Dainippon Pharma; Honoraria (self): Teijin Pharma; Honoraria (self): EA Pharma; Honoraria (self): Kaken Pharmaceutical; Advisory / Consultancy: Shire; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): ASLAN Pharmaceutical; Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharmaceutical; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Baxalta Japan Limited; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Nano Carrier; Research grant / Funding (institution): Takara-Bio. M. Ueno: Honoraria (self), Research grant / Funding (institution): Yakult Honsha; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): ASLAN; Research grant / Funding (institution): Ono pharmaceutical; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Eisai; Honoraria (self): Novel pharma; Honoraria (self): Novartis; Honoraria (self): Teijin Pharma; Research grant / Funding (institution): Takara Bio.
Resources from the same session
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract